Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 45.81 -1.05 (-2.24%) Market Cap: 3.61 Bil Enterprise Value: 2.85 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 35/100

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 09:30PM GMT
Release Date Price: $24.65 (-3.37%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference today with Crinetics. I'm joined by the company's CEO, Scott Struthers, who's going to give a presentation on the business, and then we're going to follow that up with some Q&A. (Operator Instructions)

So with that, let me pass it over to Scott.

R. Scott Struthers
Crinetics Pharmaceuticals, Inc. - Founder, President, CEO & Director

Thanks, Jess. Thanks for the invite, and thanks for the opportunity to talk to you and the team and all our investors out there in the virtual world. I'll be flipping through slides and giving slide numbers, which the group can follow along on their own.

And first, just start by referring people to our safe harbor statements since I will be making forward-looking statements.

But if the audience will go to Slide 3, I just wanted to start by saying we had a remarkable year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot